Ecolab (ECL) Q4 FY25 earnings call: guidance and Q&A

Could you elaborate on the expected trajectory for organic volumes throughout 2026, considering headwinds from Paper/Basic Industries and distributor inventories, versus momentum in other businesses?

Management expects Q1 volumes to be similar to Q4, with acceleration through the year. This is driven by 85% of businesses performing well (F&B +5%, Life Science +7%, Pest +7%, Water ex-Paper/Basic +5%, I&S ex-distributor +4%), improving performance in Paper/Basic, and normalization of distributor inventories.

“I expect the Q1 to be pretty similar to Q4, but with acceleration towards the end of the quarter and acceleration continuing in the quarters to come during the year of 2026.”

asked by Timothy Mulrooney · answered by Christophe Beck

Please provide more detail on the Global High-Tech segment, including growth rates, opportunities, and potential roadblocks, especially after the Ovivo acquisition.

Global High-Tech is a new business focused on data centers and fabs, driven by booming AI demand and critical water needs. Ovivo provides ultra-pure water solutions for fabs, enabling circular water use. For data centers, the shift to liquid cooling, especially direct-to-chip, presents significant opportunities. The combined business is roughly $1 billion, growing strong double-digits with high margins, with many opportunities for future growth.

“Today, combined, these 2 businesses are roughly $1 billion, growing strong double-digit right now at very high margin. And we see many opportunities to make that business way bigger in the years to come.”

asked by Manav Patnaik · answered by Christophe Beck

Can you provide more color on the drivers for the 100-150 basis points of margin expansion, including One Ecolab savings, pricing, and mix shift?

The margin expansion is anchored on 75-100 bps annual gross margin improvement (from value-based pricing, mix shift to higher-margin businesses, and innovation) and 25-50 bps annual SG&A leverage. One Ecolab savings, now targeted at $325 million by 2027, contributes significantly to SG&A leverage, with $100 million achieved by end of 2025 and the remaining $200 million spread equally over the next two years.

“And that $325 million, as we think about it, about $120 million. So think of sort of 1/3, 1/3, 1/3, a little bit more than 1/3 through the end of '25. And then the remaining $200 million will be sort of equally over the next 2 years.”

asked by Ashish Sabadra · answered by Scott Kirkland

Why are there such different incremental margins between Pest Elimination and Life Sciences, and how should we think about this going forward?

Life Sciences' lower Q4 OI growth was expected due to investments and a tough year-on-year comparison from performance-based compensation in 2025. Full-year OI growth for Life Sciences was 30%, and it's expected to increase double-digits in 2026. Pest's strong performance was partly due to an easier comparison from a spike in accidents in the prior year, but the business is fundamentally strong with 7% top-line growth and over 20% OI margins, expected to continue its trajectory.

“But we really expect that business going forward to increase that OI to increase double digits into '26 and going forward.”

asked by John McNulty · answered by Scott Kirkland

What is the FX outlook included in the guidance, and are water volume improvements driven by easier comps or actual industry recovery?

FX is expected to be neutral for 2026, possibly slightly favorable in H1 but offset by higher tax rates (20.5-21.5%) and a $20 million decrease in other income due to pension assumptions. Water volume improvements are driven by strong new business wins across all segments, including challenged ones like Paper and Basic Industries, which are seeing record new business despite lower overall demand. The underlying water business (ex-Paper/Basic) grew 5% organically in Q4.

“So on the FX for '26, we're not expecting a significant help or hurt. We're sort of thinking it's neutral to the year.”

asked by Andrew J. Wittmann · answered by Scott Kirkland

Can you provide details on Ovivo's sales and EBIT/EBITDA, the balance between equipment and consumables, and why its Q4 financials were excluded from reported results?

Ovivo's annual sales are roughly $0.5 billion and growing double-digit. It's primarily a technology business with less consumables, but combined with Ecolab, it becomes more consumables-driven. Ovivo's Q4 financials were excluded to show underlying business performance without transaction noise, consistent with past acquisitions, as the deal closed mid-December resulting in minimal sales/OI benefit but some interest expense.

“Ovivo as such, is mostly technology and much less consumable. What's important to us is the combination of Ecolab and Ovivo, which then becomes very much like an Ecolab business where it's mostly consumables and technology as a secondary growth driver.”

asked by Jeff Zekauskas · answered by Christophe Beck

What is the current penetration of the IQ suite, where is it headed, and how does it impact growth, digital sales, and margins?

Penetration of the IQ suite is currently in the low single digits, indicating a very early stage. The impact is seen across all three areas: it contributes to digital sales (which are included in the traditional four segments), drives volume growth, and improves margins due to the higher profitability of digital offerings. The company sees significant potential given the vast customer base and the shift in cost barriers for technology adoption.

“The short answer is all 3, Mike. So first your question, penetration. It's in the low single digit today. So we're very early here.”

asked by Mike Harrison · answered by Christophe Beck